Major adverse kidney events as an endpoint in acute kidney injury trials: is it time for a RE-MAKE?
作者信息
Fuhrman Dana Y, Bagshaw Sean M, Goldstein Stuart L, Legrand Matthieu, Shaw Andrew D
机构信息
UPMC Children's Hospital of Pittsburgh, 4401 Penn Avenue, Suite 2000, Pittsburgh, PA, 15224, USA.
Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton, AB, Canada.
出版信息
Intensive Care Med. 2024 Oct;50(10):1723-1724. doi: 10.1007/s00134-024-07602-5. Epub 2024 Aug 15.
Abstract
摘要
相似文献
1
Major adverse kidney events as an endpoint in acute kidney injury trials: is it time for a RE-MAKE?将主要不良肾脏事件作为急性肾损伤试验的一个终点：是时候重新制定标准了吗？
Intensive Care Med. 2024 Oct;50(10):1723-1724. doi: 10.1007/s00134-024-07602-5. Epub 2024 Aug 15.
2
Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology.急性肾损伤临床试验设计：来自 NIDDK 临床试验方法学研讨会的报告。
Clin J Am Soc Nephrol. 2012 May;7(5):844-50. doi: 10.2215/CJN.12791211. Epub 2012 Mar 22.
3
Designing clinical trials in acute kidney injury.急性肾损伤临床试验的设计
Clin J Am Soc Nephrol. 2012 May;7(5):842-3. doi: 10.2215/CJN.12801211. Epub 2012 Mar 22.
4
Endpoints for Clinical Trials of Acute Kidney Injury.急性肾损伤临床试验的终点。
Nephron. 2018;140(2):111-115. doi: 10.1159/000493203. Epub 2018 Sep 11.
5
What can we expect from biomarkers for acute kidney injury?对于急性肾损伤的生物标志物，我们能有什么期待？
Biomark Med. 2014;8(10):1239-45. doi: 10.2217/bmm.14.82.
6
Systematic review and consensus definitions for the Standardised Endpoints in Perioperative Medicine (StEP) initiative: renal endpoints.系统评价和共识定义标准化围手术期医学（StEP）倡议的标准终点：肾脏终点。
Br J Anaesth. 2018 Nov;121(5):1013-1024. doi: 10.1016/j.bja.2018.08.010. Epub 2018 Sep 21.
7
AKI-A Relevant Safety End Point?急性肾损伤——相关的安全终点？
Am J Kidney Dis. 2020 Apr;75(4):508-512. doi: 10.1053/j.ajkd.2019.11.010. Epub 2020 Feb 7.
8
Acute kidney injury biomarkers and endpoints for clinical trials.急性肾损伤临床试验的生物标志物与终点指标
Contrib Nephrol. 2011;171:208-212. doi: 10.1159/000327326. Epub 2011 May 23.
9
Urinary Biomarkers and Kidney Injury in VA NEPHRON-D: Phenotyping Acute Kidney Injury in Clinical Trials.VA NEPHRON-D 中的尿生物标志物与肾损伤：临床试验中急性肾损伤的表型研究。
Am J Kidney Dis. 2024 Feb;83(2):151-161. doi: 10.1053/j.ajkd.2023.07.012. Epub 2023 Sep 17.
10
New biomarkers of acute kidney injury: promise for the future but beware the lure of novelty.急性肾损伤的新型生物标志物：前景可期，但谨防新奇事物的诱惑。
Crit Care Med. 2009 Feb;37(2):766-7. doi: 10.1097/CCM.0b013e318194dfd0.
本文引用的文献
1
Heterogeneity in the definition of major adverse kidney events: a scoping review.主要不良肾脏事件定义中的异质性：范围综述。
Intensive Care Med. 2024 Jul;50(7):1049-1063. doi: 10.1007/s00134-024-07480-x. Epub 2024 May 27.
2
Hierarchical endpoints in critical care: A post-hoc exploratory analysis of the standard versus accelerated initiation of renal-replacement therapy in acute kidney injury and the intensity of continuous renal-replacement therapy in critically ill patients trials.重症监护中的分层终点：急性肾损伤中肾脏替代治疗标准启动与加速启动以及危重症患者连续肾脏替代治疗强度的事后探索性分析。
J Crit Care. 2024 Aug;82:154767. doi: 10.1016/j.jcrc.2024.154767. Epub 2024 Mar 11.
3
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure.一项关于肾小球滤过率（GFR）斜率作为肾衰竭替代终点的荟萃分析。
Nat Med. 2023 Jul;29(7):1867-1876. doi: 10.1038/s41591-023-02418-0. Epub 2023 Jun 17.
4
Patient engagement in Canada: a scoping review of the 'how' and 'what' of patient engagement in health research.加拿大的患者参与：对健康研究中患者参与的“方式”和“内容”的范围综述。
Health Res Policy Syst. 2018 Feb 7;16(1):5. doi: 10.1186/s12961-018-0282-4.
5
Models of preventable disease: contrast-induced nephropathy and cardiac surgery-associated acute kidney injury.可预防疾病模型：对比剂肾病与心脏手术相关急性肾损伤
Contrib Nephrol. 2011;174:156-162. doi: 10.1159/000329387. Epub 2011 Sep 9.
Zotero 插件